DuoNeb

DuoNeb is a brand name of albuterol/ipratropium, approved by the FDA in the following formulation(s):

DUONEB (albuterol sulfate; ipratropium bromide - solution; inhalation)

• 
  Manufacturer: DEY
  
  Approval date: March 21, 2001
  
  Strength(s): EQ 0.083% BASE;0.017% ^[RLD][AN]

Has a generic version of DuoNeb been approved?

A generic version of DuoNeb has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to DuoNeb and have been approved by the FDA:

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE (albuterol sulfate; ipratropium bromide solution; inhalation)

• 
  Manufacturer: APOTEX CORP
  
  Approval date: December 31, 2007
  
  Strength(s): EQ 0.083% BASE;0.017% ^[AN]


• 
  Manufacturer: NEPHRON
  
  Approval date: December 31, 2007
  
  Strength(s): EQ 0.083% BASE;0.017% ^[AN]


• 
  Manufacturer: SANDOZ
  
  Approval date: December 21, 2006
  
  Strength(s): EQ 0.083% BASE;0.017% ^[AN]


• 
  Manufacturer: TEVA PARENTERAL
  
  Approval date: December 31, 2007
  
  Strength(s): EQ 0.083% BASE;0.017% ^[AN]


• 
  Manufacturer: WATSON LABS
  
  Approval date: December 31, 2007
  
  Strength(s): EQ 0.083% BASE;0.017% ^[AN], EQ 0.083% BASE;0.017% ^[AN]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of DuoNeb. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
  Patent 6,632,842
  Issued: October 14, 2003
  Inventor(s): Imtiaz; Chaudry & Partha; Banerjee
  Assignee(s): Dey, L.P.
  The present invention relates to a dual bronchodilator inhalation solution, system, kit and method for relieving bronchospasm in patients suffering from chronic obstructive pulmonary disease (COPD). In one alternative embodiment, the solution of the present invention is a prepackaged, sterile, premixed, premeasured single unit dose of albuterol and ipratropium bromide for patients suffering from COPD. The present solution may be free of antimicrobial preservatives, such as benzalkonium chloride. In another alternative embodiment, the solution of the present invention comprises about 2.50 mg albuterol and about 0.50 mg ipratropium bromide.
  
  Patent expiration dates:
  
  
  • December 28, 2021
    
    ✓ 
    Patent use: TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR
  
  

See also...

• DuoNeb Consumer Information (Drugs.com)
• DuoNeb Solution Consumer Information (Wolters Kluwer)
• DuoNeb inhalation Consumer Information (Cerner Multum)
• Duoneb Advanced Consumer Information (Micromedex)
• Albuterol/Ipratropium Aerosol Consumer Information (Wolters Kluwer)
• Albuterol/Ipratropium Solution Consumer Information (Wolters Kluwer)
• Albuterol and ipratropium inhalation Consumer Information (Cerner Multum)
• Ratio-Ipra Sal Udv Advanced Consumer Information (Micromedex)
• Ipratropium and albuterol Inhalation, oral/nebulization Advanced Consumer Information (Micromedex)